Affordability and Safety: How Hims & Hers is Delivering a New GLP-1 Experience Through the Scale of Our Platform

For nearly 7 years and over 20 million consultations on our platform since our founding, we’ve taken this customer-centric approach with all kinds of sensitive, challenging conditions: breaking down barriers to accessing care, whether through raising awareness, removing stigma, improving access channels, and meaningfully lowering the cost of high-quality care. Making GLP-1 medications available through our platform, which we’re announcing today, is very much in line with that ethos.

When we first built our weight loss solution, we prioritized access to non-GLP-1 treatments, including some that had been used for decades to successfully help people lose weight. We knew GLP-1s were not for everyone and the shortages across the industry made GLP-1s too expensive and too challenging to physically access. As we shared in our Q1 earnings date, this solution continues to perform as expected and is projected to generate over $100 million in revenue by 2025. However, it is now clear that the portfolio of GLP-1 drugs will remain in shortage for some amount of time – and at Hims & Hers, we believe any amount of time is too long to wait for the care you deserve and the treatments you need. 

The ongoing shortage of GLP-1 medications is placing an immense strain on the millions of Americans who have obesity, are looking for help, and cannot access the care that they deserve. Drugs that currently cost thousands out of pocket for a monthly supply can be accessed for much, much less – and at Hims & Hers we believe those savings should be passed to consumers. We conducted extensive research for over a year into the FDA’s exhaustive list of approved 503B pharmacies, putting rigorous standards in place for vetting and we’re now partnering with a leading US manufacturer of generic and 503B compounded injectable medications as our supplier for these drugs. We are leveraging our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1s available today in order to be a part of easing the strain this shortage is placing on the millions of Americans who have obesity and are looking for help. 

Many of the current challenges with GLP-1s are driven by persistent shortages, arbitrarily high costs of medications, providers’ inability to truly personalize treatments based on their individual patients’ responses, and a one-size-fits-all approach to dosing. The elements preventing us from building a GLP-1 offering – pricing, availability of the active ingredients, confidence in the quality of the compounded versions of the drugs – have evolved significantly over the last year and, given our success over the last few quarters, we have found a way to mitigate those challenges on the behalf of our customers. We’ve always said that we feel it’s important to be the best in market, rather than simply the first in market.

Over the last year, we have grown in our conviction – based on our medical experts’ evaluation and the strength of our infrastructure – that if done properly, compounded GLP-1s are safe and effective. Similar to our extensive work in mental health where we’ve served hundreds of thousands of customers, we know that not all medications are right for all people, which means a broader offering that focuses on personalization in treatment is necessary for great outcomes. We have taken a holistic approach to weight loss because we are committed to providing a comprehensive set of options so individuals and their providers can find a solution that is right for them. That means (in addition to sleep, movement and nutrition tools) offering the option of oral medications, compounded GLP-1s, or branded GLP-1 medications (as supply becomes more readily available), so that customers can truly personalize their experience. 

Starting today, we are providing access to compounded GLP-1 treatments for eligible customers at prices starting at $199/monthly. We are providing access to compounded GLP-1s, which means customers can access the same active ingredient as Ozempic and Wegovy without navigating the shortages that are currently limiting access to the medication. However, we know that some customers will still prefer a branded medication, so we’re built to offer access to those as well, as supply becomes more readily available. Through our offering, we’re delivering a personalized approach for every customer that is affordable and built to deliver successful outcomes. 

Our experience serving more than 1.7M subscribers¹, combined with our infrastructure, gives us confidence that this is the best time to begin offering access to GLP-1s. After a year of evaluating this space with our clinical partners, we believe we can deliver equal – if not better – experiences for the millions of people who deserve to find success with a solution that has been personalized for their needs. This is another chance for us to make good on our promise to customers of access to affordable, available treatments that meet our high clinical standards, and I can’t wait to see the lives we impact.